Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

PURPOSE: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (...

詳細記述

保存先:
書誌詳細
出版年:Int J Chron Obstruct Pulmon Dis
主要な著者: Miravitlles, Marc, Gáldiz, Juan B, Huerta, Alicia, Villacampa, Alba, Carcedo, David, Garcia-Rio, Francisco
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2016
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723026/
https://ncbi.nlm.nih.gov/pubmed/26848262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S94006
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料